Literature DB >> 30393599

Is more the better?-cetuximab in non-small cell lung cancer patients.

Teresa Moran1.   

Abstract

Entities:  

Year:  2018        PMID： 30393599      PMCID： PMC6193895          DOI： 10.21037/tlcr.2018.04.14

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  12 in total

1.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Authors:  Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

3.  Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy.

Authors:  Brian M Alexander; Jonathan D Schoenfeld; Lorenzo Trippa
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

4.  Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.

Authors:  Ana Victoria López-Malpartida; María Dolores Ludeña; Gonzalo Varela; José García Pichel
Journal:  Lung Cancer       Date:  2008-11-28       Impact factor: 5.705

5.  Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Authors:  Roy S Herbst; Mary W Redman; Edward S Kim; Thomas J Semrad; Lyudmila Bazhenova; Gregory Masters; Kurt Oettel; Perry Guaglianone; Christopher Reynolds; Anand Karnad; Susanne M Arnold; Marileila Varella-Garcia; James Moon; Philip C Mack; Charles D Blanke; Fred R Hirsch; Karen Kelly; David R Gandara
Journal:  Lancet Oncol       Date:  2017-11-20       Impact factor: 41.316

6.  Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

Authors:  Fred R Hirsch; Roy S Herbst; Christine Olsen; Kari Chansky; John Crowley; Karen Kelly; Wilbur A Franklin; Paul A Bunn; Marileila Varella-Garcia; David R Gandara
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

7.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

8.  Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

Authors:  Edward S Kim; James Moon; Roy S Herbst; Mary W Redman; Shaker R Dakhil; Mario R Velasco; Fred R Hirsch; Philip C Mack; Karen Kelly; John V Heymach; David R Gandara
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

9.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Authors:  Shirin Khambata-Ford; Christopher T Harbison; Lowell L Hart; Melissa Awad; Li-An Xu; Christine E Horak; Shaker Dakhil; Robert C Hermann; Thomas J Lynch; Martin R Weber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Authors:  Thomas J Lynch; Taral Patel; Luke Dreisbach; Michael McCleod; William J Heim; Robert C Hermann; Eugene Paschold; Nicholas O Iannotti; Shaker Dakhil; Steven Gorton; Virginie Pautret; Martin R Weber; Donald Woytowitz
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
View more
  1 in total

1.  Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells.

Authors:  Jian Cui; Jun Wang; Chao Lin; Jixiang Liu; Wei Zuo
Journal:  Onco Targets Ther       Date:  2019-11-26       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.